PMID- 29702540
OWN - NLM
STAT- MEDLINE
DCOM- 20190319
LR  - 20190319
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 40
IP  - 5
DP  - 2018 Jul
TI  - Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving 
      Hematopoietic Stem Cell Transplantation.
PG  - e278-e282
LID - 10.1097/MPH.0000000000001186 [doi]
AB  - BACKGROUND: Many children undergoing hematopoietic stem cell transplantation 
      (HSCT) experience chemotherapy-induced nausea and vomiting (CINV) despite 
      receiving prophylaxis. Guideline-consistent CINV prophylaxis includes 
      dexamethasone, but uncertainty with regard to safety potentially limits the use 
      of dexamethasone in children. We describe immediate adverse events (AEs) 
      attributable to dexamethasone given for CINV prophylaxis to children during HSCT 
      conditioning. MATERIALS AND METHODS: Children enrolled in a previous prospective 
      study were retrospectively analyzed. Objective parameters related to specific AEs 
      occurring within 5 days of dexamethasone administration were abstracted from 
      health records and graded according to the Common Terminology Criteria for 
      Adverse Events version 4.03 (CTCAE v4.03). Their association to dexamethasone was 
      assessed using the Liverpool Causality Assessment Tool. RESULTS: Forty-six 
      children (median age, 10.2 y) were eligible for analysis. The most frequent AEs 
      attributable to dexamethasone (Liverpool Causality Assessment Tool category of 
      probable or definite) were hyperglycemia (63%; CTCAE v4.03 grade 3: 2%), 
      hypertension (52%; CTCAE v4.03 grade 3: 15%), and bradycardia (46%; CTCAE v4.03 
      grade 3: 0%). Other AEs included dyspepsia or gastroesophageal reflux disease 
      (24%) and alterations in mood and behavior (9%). No AE exceeded CTCAE v4.03 grade 
      3 in severity. CONCLUSIONS: In children undergoing HSCT who received 
      dexamethasone for CINV prophylaxis, immediate AEs attributable to dexamethasone 
      were most often of minor clinical importance and transient.
FAU - Paw Cho Sing, Edric
AU  - Paw Cho Sing E
AD  - Department of Pharmacy.
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
FAU - Schechter, Tal
AU  - Schechter T
AD  - Department of Paediatrics, Division of Hematology/Oncology.
FAU - Ali, Muhammad
AU  - Ali M
AD  - Department of Paediatrics, Division of Hematology/Oncology.
FAU - Sung, Lillian
AU  - Sung L
AD  - Department of Paediatrics, Division of Hematology/Oncology.
AD  - Child Health Evaluative Sciences, Research Institute, The Hospital for Sick 
      Children.
FAU - Dupuis, L Lee
AU  - Dupuis LL
AD  - Department of Pharmacy.
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
AD  - Child Health Evaluative Sciences, Research Institute, The Hospital for Sick 
      Children.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Dexamethasone/*administration & dosage/adverse effects
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Nausea/chemically induced/*prevention & control
MH  - Vomiting/chemically induced/*prevention & control
EDAT- 2018/04/28 06:00
MHDA- 2019/03/20 06:00
CRDT- 2018/04/28 06:00
PHST- 2018/04/28 06:00 [pubmed]
PHST- 2019/03/20 06:00 [medline]
PHST- 2018/04/28 06:00 [entrez]
AID - 10.1097/MPH.0000000000001186 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2018 Jul;40(5):e278-e282. doi: 
      10.1097/MPH.0000000000001186.